Allison O'Neill, MD
Clinical Director, Solid Tumor Center; Director of Medical Therapies, Liver Tumor Center; Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Vice President for Clinical Performance Management, Dana-Farber Cancer Institute
Associate Professor of Pediatrics, Harvard Medical School
Image
Allison O'Neill, MD
Clinical Director, Solid Tumor Center; Director of Medical Therapies, Liver Tumor Center; Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Vice President for Clinical Performance Management, Dana-Farber Cancer Institute
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Spanish
Education
Medical School
Albert Einstein College of Medicine
2005
Bronx
NY
US
Internship
Boston Children's Hospital/Boston Medical Center
2006
Boston
MA
US
Residency
Pediatrics
Boston Children's Hospital/Boston Medical Center
Boston
MA
US
Fellowship
Pediatric Hematology-Oncology
Dana-Farber Cancer Institute
2011
Boston
MA
US
Media
Caregiver Profile
Meet Dr. Allison O'Neill
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Hematology-Oncology)
Professional History
I am a Pediatric Oncology physician-scientist with an interest in translational research and a growing expertise in the care of pediatric solid tumor patients. I have followed a unique path, focused initially on the use of imaging to enhance diagnostics and therapeutics in pediatric solid tumor patients, now with an increasing interest in the Ewing sarcoma cell surfaceome and immune environment. My prior work generating a targeted imaging probe to more sensitively and specifically diagnose Ewing sarcoma micro-metastases inspired a growing interest in targeted immunotherapeutics. My subsequent training in cancer immunology, including but not limited to antibody humanization, characterization, and engineering, has generated the skills necessary to pursue novel immunotherapeutics for pediatric patients. In concert with my preclinical training, I have focused on developing clinical solid tumor expertise, recognizing my career goals of becoming a leader in the care of solid tumor patients with a focus on translational research and innovation.
I lead the Dana-Farber/Boston Children’s pediatric Liver Tumor Center, working closely with surgeons, interventional radiologists, and preclinical researchers to bring innovative care to patients with all types of primary liver tumors. I serve as Chair of the Children’s Oncology Group Liver Tumor Committee and work closely with international colleagues affiliated with the Paediatric Hepatic International Tumour Trial (PHITT) and SIOP Liver Tumor Working Group. My unique split between patient care and research has allowed an opportunity to develop and refine skills in teaching medical students, residents and fellows; training laboratory technicians and post-doctoral fellows; and counseling trainees regarding the intricacies relevant to a career in translational research. With continued support from a multidisciplinary team, I hope to bring the power of cancer imaging and immunotherapy to bear on the diagnosis and treatment of pediatric solid tumor patients.
Publications
Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy. View Abstract
Hepatoblastoma. View Abstract
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. View Abstract
Pediatric Hepatocellular Carcinoma: A Review of Predisposing Conditions, Molecular Mechanisms, and Clinical Considerations. View Abstract
Characteristics of patients with liver tumors deemed ineligible for enrollment on Children's Oncology Group trial AHEP1531: An opportunity to expand inclusion criteria and improve outcome. View Abstract
Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative. View Abstract
Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children's hepatic tumors international collaboration database. View Abstract
Pediatric Adrenocortical Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future Discovery. View Abstract
Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series. View Abstract
Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature. View Abstract
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. View Abstract
Anti-CD99 Antibody Therapy Triggers Macrophage-Dependent Ewing Cell Death In Vitro and Myeloid Cell Recruitment In Vivo. View Abstract
The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution. View Abstract
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. View Abstract
Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature. View Abstract
Cancer Therapy-related Hepatic Injury in Children: Imaging Review from the Pediatric LI-RADS Working Group. View Abstract
Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. View Abstract
Children's Oncology Group's 2023 blueprint for research: Liver tumors. View Abstract
Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective. View Abstract
Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC). View Abstract
A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. View Abstract
Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee. View Abstract
Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data. View Abstract
Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it. View Abstract
Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children's Hepatic Tumors International Collaboration (CHIC). View Abstract
Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731. View Abstract
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. View Abstract
A framework for fibrolamellar carcinoma research and clinical trials. View Abstract
Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. View Abstract
Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study. View Abstract
Fibrolamellar carcinoma: An entity all its own. View Abstract
Undifferentiated Embryonal Sarcoma of the Liver With Rhabdoid Morphology Mimicking Carcinoma: Expanding the Morphologic Spectrum or a Distinct Variant? View Abstract
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. View Abstract
A serous borderline ovarian tumour in a transgender male adolescent. View Abstract
Timely pediatric cancer diagnoses: An unexpected casualty of the COVID-19 surge. View Abstract
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. View Abstract
Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. View Abstract
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. View Abstract
The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. View Abstract
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. View Abstract
Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. View Abstract
BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. View Abstract
a-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. View Abstract
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. View Abstract
Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. View Abstract
Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. View Abstract
Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. View Abstract
Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. View Abstract
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. View Abstract
Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. View Abstract
Unresectable hepatoblastoma: current perspectives. View Abstract
Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. View Abstract
Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. View Abstract
Post-transplant lymphoproliferative disorder of the pediatric airway: Presentation and management. View Abstract
Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. View Abstract
Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. View Abstract
Ludwig's angina following frenuloplasty in an adolescent. View Abstract
Ludwig's angina in the pediatric population. View Abstract
Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function. View Abstract
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. View Abstract
Are there universal parenting concepts among culturally diverse families in an inner-city pediatric clinic? View Abstract
Regulation of Ca(2+) signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. View Abstract
Regulation of the type III InsP(3) receptor by InsP(3) and calcium. View Abstract
The type II inositol 1,4,5-trisphosphate receptor can trigger Ca2+ waves in rat hepatocytes. View Abstract
A primitive ATP receptor from the little skate Raja erinacea. View Abstract
Primitive organization of cytosolic Ca(2+) signals in hepatocytes from the little skate Raja erinacea. View Abstract